Congressional Oversight of Medicare Program Intensifies: A Look at the Factors Surrounding the Scrutiny and Nephrology's Response

Advances in Chronic Kidney Disease

Volumn 15, Issue 1, 2008, Pages 10-14

  Blaser, Robert E ^a   Kliger, Alan S ^a  

^a HOSPITAL OF SAINT RAPHAEL   (United States)

Author keywords

Congress; Erythropoiesis stimulating agents; Hemoglobin; Nephrology; Oversight; Pay for performance; Quality measurement; Value based purchasing

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; HEALTH CARE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; LAW; MEDICARE; ORGANIZATION; PATIENT CARE; PRIORITY JOURNAL;

ANEMIA; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); DOCUMENTATION; HEALTH POLICY; HEMATINICS; HUMANS; INSURANCE CLAIM REPORTING; KIDNEY FAILURE, CHRONIC; MEDICARE; NEPHROLOGY; PHYSICIANS; POLITICS; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES; VOLUNTARY PROGRAMS;

EID: 37248999935     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2007.10.001     Document Type: Article

References (16)

1. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
2. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
3. Thamer M., Zhang Y., Kaufman J., et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
4. Thomas B. Hearing on Patient Safety and Quality Issues in End Stage Renal Disease Treatment. Means CoWa; U.S. House of Representatives 109 (2006) 87
5. Walker DM: Testimony Before the Committee on Ways and Means, House of Representatives. End-Stage Renal Disease: Medicare Payments for All ESRD Services, Including Injectable Drugs, Should Be Bundled, Office USGA, 2006
6. FDA Strengthens Safety Information for Erythropoiesis-Stimulating Agents (ESAs). Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01582.html. Accessed August 20, 2007
7. Pollack A: Anemia drugs under review by Congress. New York Times, Business section, March 22, 2007
8. Pollack A: F.D.A. warning is issued on anemia drugs' overuse. New York Times, Washington section, March 10, 2007
9. U.S. to review anemia drugs for safety. New York Times, Business section, March 15, 2007
10. To Err is Human (1999), Institute of Medicine/National Academies Press, Washington, DC
11. st Century (2001), Institute of Medicine/National Academies Press, Washington, DC
12. Physician Quality Reporting Initiative. Available at: http://www.cms.hhs.gov/pqri/. Accessed August 8, 2007
13. Physician Quality Reporting Initiative-Measures/Codes. Available at: http://www.cms.hhs.gov/PQRI/15_MeasuresCodes.asp#TopOfPage. Accessed August 8, 2007
14. Participation Tools: Medicare Physician Quality Reporting Initiative (PQRI). Available at: http://www.ama-assn.org/ama/pub/category/17432.html. Accessed August 10, 2007
15. Tax Relief and Health Care Act of 2006, Pub. L. no 109-432, 2006
16. Centers for Medicare and Medicaid Services (CMS), Pub 100-04 Medicare Claims Processing, Transmittal 751, Change Request 4135; National Monitoring Policy for EPO and Aranesp for End Stage Renal Disease (ESRD) Patients Treated in Renal Dialysis Facilities; November 10, 2005